Amgen takes 20% stake in Chinese biotech BeiGene for $2.7 billion
October 31, 2019 at 16:00 PM EDT
Under the all-cash deal, Amgen will pay BeiGene shareholders $174.85 per share, a 25% premium to BeiGene's closing price on the Nasdaq on Wednesday.
